Skip to main content

Table 4 Pre-treatment serum concentration and urinary excretion of MIF in patients with proliferative and non-proliferative glomerulonephritis (GN) after division into Responders (R) and Non-Responders (NR) subgroups

From: Macrophage migration inhibitory factor urinary excretion revisited – MIF a potent predictor of the immunosuppressive treatment outcomes in patients with proliferative primary glomerulonephritis

 

Serum MIF (ng/ml)

Urinary MIF (ng/mg Cr)

Mean ± SD

Median (range)

Mean ± SD

Median (range)

Proliferative GN

R

1.3 ± 0.8

1.4 (1.1–1.5)

2.1 ± 1.3

2.4 (2.0–3.7)

NR

3.3 ± 1.2

3.0 (2.0–3.4)

5.9 ± 2.9

6.1a,b,c (2.9–8.1)

Non-proliferative GN

R

1.7 ± 0.2

1.8 (1.0–2.0)

2.9 ± 1.8

2.2 (1.7–4.1)

NR

2.0 ± 0.4

1.9 (1.2–2.4)

3.1 ± 2.1

2.3 (1.9–4.3)

  1. Differences were considered significant for P < 0.05 (Kruskal-Wallis ANOVA)
  2. aProliferative GN NR versus proliferative GN R
  3. bProliferative GN NR versus non-proliferative GN R
  4. cProliferative GN NR versus non-proliferative GN NR
Back to article page

BMC Immunology

ISSN: 1471-2172

Contact us